Refine Search

Search Results -

Terms	Documents
L13 and (SPD or MBL$ or SPA or collectin-43)	31

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L15

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Thursday, October 19, 2006 Purge Queries | Printable Copy | Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L15	L13 and (SPD or MBL$ or SPA or collectin-43)	31	L15
L14	L13 and collectin$	29	L14
L13	l7 and chimeric	203	L13
L12	l7 with chimeric	0	L12
L11	l7 and collectins	2	L11
L10	L8 and (fusion or heterologous)	81	L10
L9	L8 with (fusion or heterologous)	0	L9
L8	L7 with ligand	82	L8
L7	(tumor adj necrosis adj factor adj superfamily) or ((tumor adj necrosis adj factor) with superfamily)	259	L7
L6	L5 and ligand	9	L6
L5	(tumor adj necrosis adj factor adj superfamily)	10	L5
L4	TNFSF	0	L4

L3	TNFSF adj ligand	0	L3
L2	L1 with TNFSF	0	L2
L1	extracellualr adj domain	4	L1

END OF SEARCH HISTORY

```
**********STN Columbus ****
**********

FILE 'HOME' ENTERED AT 11:26:39 ON 19
OCT 2006

=> file medline caplus biosis embase
uspatful
COST IN U.S. DOLLARS
SINCE FILE     TOTAL
                                ENTRY
SESSION
FULL ESTIMATED COST
0.21      0.21

FILE 'MEDLINE' ENTERED AT 11:27:24 ON
19 OCT 2006

FILE 'CAPLUS' ENTERED AT 11:27:24 ON
19 OCT 2006
USE IS SUBJECT TO THE TERMS OF
YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR
DETAILS.
COPYRIGHT (C) 2006 AMERICAN
CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 11:27:24 ON
19 OCT 2006
Copyright (c) 2006 The Thomson
Corporation

FILE 'EMBASE' ENTERED AT 11:27:24 ON
19 OCT 2006
Copyright (c) 2006 Elsevier B.V. All rights
reserved.

FILE 'USPATFULL' ENTERED AT 11:27:24
ON 19 OCT 2006
CA INDEXING COPYRIGHT (C) 2006
AMERICAN CHEMICAL SOCIETY (ACS)

=> s collectin? (W) (fusion or chimeric)
L1         13 COLLECTIN? (W) (FUSION OR
CHIMERIC)

=> s l1 and TNFSF
L2          2 L1 AND TNFSF

=> duplicate remove l2
DUPLICATE PREFERENCE IS 'CAPLUS,
USPATFULL'
KEEP DUPLICATES FROM MORE THAN
ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L2
L3          2 DUPLICATE REMOVE L2 (0
DUPLICATES REMOVED)

=> d l3 1- ibib, abs
YOU HAVE REQUESTED DATA FROM 2
ANSWERS - CONTINUE? Y/(N):y

L3  ANSWER 1 OF 2  USPATFULL on STN
ACCESSION NUMBER:      2005:183444
USPATFULL <<LOGINID::20061019>>
TITLE:                 Multimeric fusion proteins
of TNF superfamily ligands
INVENTOR(S):           Kornbluth, Richard
S., La Jolla, CA, UNITED STATES

                       NUMBER      KIND
DATE
                       ----------- ------ --------
PATENT INFORMATION:    US
2005158831      A1   20050721
APPLICATION INFO.:     US 2005-87348
A1   20050322  (11)
RELATED APPLN. INFO.:  Continuation of
Ser. No. US 1999-454223, filed on 9 Dec
                       1999, PENDING

                         NUMBER       DATE
                         ------------ --------
PRIORITY INFORMATION:  US 1998-
111471P    19981209 (60)
DOCUMENT TYPE:         Utility
FILE SEGMENT:          APPLICATION
LEGAL REPRESENTATIVE:  Lisa A. Haile,
J.D., Ph.D., DLA PIPER RUDNICK GRAY
CARY
                       US LLP, Suite 1100, 4365
Executive Drive, San Diego,
                       CA, 92121-2133, US
NUMBER OF CLAIMS:      24
EXEMPLARY CLAIM:       1-15
NUMBER OF DRAWINGS:    7 Drawing
Page(s)
LINE COUNT:            1657
CAS INDEXING IS AVAILABLE FOR THIS
PATENT.
AB    A method for constructing stable
bioactive fusion proteins of the
      difficult to express turn or necrosis
factor superfamily (  ***TNFSF***
      ), and particularly members CD40L (CD
154) and RANKL/TRANCE, with
```

collectins, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these soluble fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be especially useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addition, these and other ***TNFSF*** - ***collectin*** ***fusion*** proteins present new possibilities for the expression of highly active, multimeric, soluble ***TNFSF*** members.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 2 CAPLUS
COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:435124
CAPLUS <<LOGINID::20061019>>
DOCUMENT NUMBER: 135:45182
TITLE: Multimeric forms of TNF superfamily ligands
INVENTOR(S): Kornbluth, Richard S.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042298	A1	20010614	WO 2000-US7380	20000320
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2393659	AA	20010614	CA 2000-2393659	20000320
EP 1235853	A1	20020904	EP 2000-919485	20000320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2005158831	A1	20050721	US 2005-87348	20050322

PRIORITY APPLN. INFO.: US 1999-454223 A 19991209
US 1998-111471P P 19981209
WO 2000-US7380 W 20000320

AB A method for constructing stable bioactive fusion proteins of the difficult to express tumor necrosis factor superfamily (***TNFSF***), and particularly members CD40L (CD154) and RANKL/TRANCE, with collectins, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these sol. fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be esp. useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addn., these and other ***TNFSF*** - ***collecting*** ***fusion*** proteins present new possibilities for the expression of highly active,

multimeric, sol. ***TNFSF*** members.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l1 1- ibib, abs
YOU HAVE REQUESTED DATA FROM 13 ANSWERS - CONTINUE? Y/(N):y

L1 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:252645 CAPLUS <<LOGINID::20061019>>
DOCUMENT NUMBER: 140:286164
TITLE: Fusion proteins of complement activating proteins and lectins for lectin-mediated activation of complement
INVENTOR(S): Kongerslev, Leif; Weilguny, Dietmar; Matthiesen, Finn
PATENT ASSIGNEE(S): NatImmune A/S, Den.
SOURCE: PCT Int. Appl., 127 pp. CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024925	A2	20040325	WO 2003-DK585	20030910
WO 2004024925	C1	20040521		
WO 2004024925	A3	20040624		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003260286	A1	20040430	AU 2003-260286	20030910
EP 1539964	A2	20050615	EP 2003-794818	20030910

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1694961	A	20051109	CN 2003-825026	20030910
JP 2005537807	T2	20051215	JP 2004-535018	20030910
US 2006188963	A1	20060824	US 2005-527191	20050310

PRIORITY APPLN. INFO.: DK 2002-1328 A 20020910
WO 2003-DK585 W 20030910

AB Fusion proteins of complement activating proteins that can be used to stimulate the lectin-dependent pathway of complement activation in improving the response to infection are described. The proteins are fusion products of complement-activating proteins and lectins such as collectins, L-ficolin, or mannan-binding lectins. These fusion proteins are suitable for therapeutic reconstitution or improvement of opsonic or bactericidal activity of the complement system, i.e. enhancing the ability of the immune defense to recognize and kill microbial pathogens, and accordingly, the invention relates to a medicament comprising the fusion protein, methods for producing said fusion protein and methods for treating diseases, in particular infections.

L1 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:183045 CAPLUS <<LOGINID::20061019>>
DOCUMENT NUMBER: 140:234386
TITLE: Chimeric proteins comprising lectin carbohydrate-binding domain and cell surface protein

ligand for modulating immune response to antigen
INVENTOR(S): Segal, Andrew H.; Young, Elihu
PATENT ASSIGNEE(S): Genitrix, LLC, USA
SOURCE: PCT Int. Appl., 265 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
---------- ---- -------- ---------- --------
WO 2004018698 A2 20040304 WO 2003-US26072 20030820
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2004039156 A1 20040226 US 2002-224661 20020820
CA 2496384 AA 20040304 CA 2003-2496384 20030820
AU 2003265523 A1 20040311 AU 2003-265523 20030820
US 2004091503 A1 20040513 US 2003-645000 20030820
EP 1573047 A2 20050914 EP 2003-793170 20030820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006517512 T2 20060727 JP 2004-531131 20030820
US 2004122217 A1 20040624 US 2003-666871 20030919
US 2004126793 A1 20040701 US 2003-666885 20030919
US 2004126357 A1 20040701 US 2003-666886 20030919
US 2004142889 A1 20040722 US 2003-666898 20030919
US 2004151728 A1 20040805 US 2003-666834 20030919
US 2004170960 A1 20040902 US 2003-667193 20030919
US 2004180389 A1 20040916 US 2003-667166 20030919
US 2004241137 A1 20041202 US 2003-666833 20030919
US 2005064391 A1 20050324 US 2003-668073 20030919
PRIORITY APPLN. INFO.: US 2002-224661 A 20020820
US 2002-404823P P 20020820
US 2003-487407P P 20030715
US 2003-645000 A3 20030820
WO 2003-US26072 W 20030820

AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and server as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The lectin is collectin, galectin, C-type lectin or glycoprotein; and the cell surface protein is cytokine receptor, CD40, adhesion mol., defensin receptor, heat shock protein receptor, T cell costimulatory mol., counterreceptor of T cell costimulatory mol., or opsonin receptor. The present invention also provides a compn. comprising an antigen bearing target and such a fusion polypeptide, as well as a compn. comprising a virus or a cell and such a fusion polypeptide. The antigen is tumor antigen, viral antigen, bacterial antigen, fungal antigen, parasitic antigen, prion antigen, or autoimmune disease antigen.
The present invention further relates to a method of modulating an immune

response in an animal using such compns. or vaccines.

L1 ANSWER 3 OF 13 CAPLUS
COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:550998
CAPLUS <<LOGINID::20061019>>
DOCUMENT NUMBER: 139:99846
TITLE: Vaccination with fusion opsonins targeting
antigen-presenting cells
INVENTOR(S): Segal, Andrew
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 952 pp., Cont.-in-part of U.S.
Ser. No. 789,922.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003133942	A1	20030717	US 2002-262828	20021002
US 2001031264	A1	20011018	US 2001-789922	20010221

PRIORITY APPLN. INFO.: US 2001-789922 A2 20010221
US 1996-11047P P 19960125
US 1998-7711 A2 19980115
AB The author discloses the enhancement of immune responses induced by in-frame fusion of an antigen with a binding domain of an opsonin targeting antigen-presenting cells. In one example, DNA immunization with a chimeric construct of chicken lysozyme and the .alpha.-chain of complement C3b increased the IgG1 response over that elicited by a recombinant lysozyme construct alone.

L1 ANSWER 4 OF 13 CAPLUS
COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:716866
CAPLUS <<LOGINID::20061019>>
DOCUMENT NUMBER: 137:231362
TITLE: Opsonin fusion proteins for modulation of the immune response
INVENTOR(S): Segal, Andrew
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. 6,224,870.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002131974	A1	20020919	US 2001-790317	20010221
US 6632436	B2	20031014		
US 6224870	B1	20010501	US 1998-7711	19980115

PRIORITY APPLN. INFO.: US 1996-11047P P 19960125
US 1998-7711 A2 19980115
US 1997-788143 B2 19970124
AB The authors discloses the application of in-frame translation fusion of an antigen with an APC binding domain of an opsonin to form a mol., which on administration, modulates an immune response to the antigen. In one example, the IgG1 response was shown to be enhanced for a construct of lysozyme and a fragment of the C3b .alpha.-chain.

L1 ANSWER 5 OF 13 CAPLUS
COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:368513
CAPLUS <<LOGINID::20061019>>
DOCUMENT NUMBER: 136:380110
TITLE: Apolipoprotein A analogs capable of forming HDL and with extended serum half-lives and stronger binding to cubilin for treatment of cardiovascular disease
INVENTOR(S): Graversen, Jonas; Moestrup, Soren
PATENT ASSIGNEE(S): Proteopharma Aps, Den.
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038609	A2	20020516	WO 2001-DK739	20011109
WO 2002038609	A3	20020926		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2428114	AA	20020516	CA 2001-2428114	20011109
AU 2002013843	A5	20020521	AU 2002-13843	20011109
AU 2002213843	A2	20020521	AU 2002-213843	20011109
BR 2001015257	A	20030812	BR 2001-15257	20011109
EP 1335938	A2	20030820	EP 2001-982197	20011109

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004522424	T2	20040729	JP 2002-541940	20011109
US 2002156007	A1	20021024	US 2001-987107	20011113
US 6897039	B2	20050524		
NO 2003002101	A	20030708	NO 2003-2101	20030509
ZA 2003004486	A	20040909	ZA 2003-4486	20030609
US 2005096277	A1	20050505	US 2004-17037	20041221
US 2005142639	A1	20050630	US 2004-17059	20041221

PRIORITY APPLN. INFO.: DK 2000-1682 A 20001110
DK 2001-57 A 20010115
US 2001-264022P P 20010126
WO 2001-DK739 W 20011109
US 2001-987107 A3 20011113

AB The invention relates to an apolipoprotein construct, an apolipoprotein construct for use as a medicament, a nucleic acid sequence encoding the apolipoprotein construct, a vector comprising the nucleic acid sequence, a method for producing the apolipoprotein construct, and use of the apolipoprotein construct for the prepn. of apharmaceutical compn.

Specifically, analogs and fusion proteins of apolipoprotein AI are described. The presented data document that the constructs according to the invention are capable of binding lipids, are capable of binding cubilin, which is a strong Apo AI receptor, stronger than native Apo A-I and that the plasma half life of the constructs is at least tripled compared to native Apo A-I. Together these data document that the constructs according to the invention are strong candidates for treatment of cardiovascular diseases.

L1 ANSWER 6 OF 13 CAPLUS

ACCESSION NUMBER: 2002:10696
CAPLUS <<LOGINID::20061019>>
DOCUMENT NUMBER: 136:68702
TITLE: Analysis of CD154 oligomerization on CD40 signaling using CD154- ***collectin*** ***fusion*** protein
INVENTOR(S): Al-Shamkhani, Aymen; Glennie, Martin
PATENT ASSIGNEE(S): Cancer Research Ventures Limited, UK
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE
APPLICATION NO. DATE
---------- ---- -------- ----------
-- --------
WO 2002000893 A1 20020103
WO 2001-GB2810 20010625
W: AE, AG, AL, AM, AT, AU, AZ, BA,
BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ,
EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD,
SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT,
LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW,
ML, MR, NE, SN, TD, TG
CA 2414342 AA 20020103 CA
2001-2414342 20010625
EP 1297160 A1 20030402 EP
2001-945468 20010625
R: AT, BE, CH, DE, DK, ES, FR, GB,
GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL,
TR
US 2004047873 A1 20040311
US 2003-312374 20031010
PRIORITY APPLN. INFO.: GB
2000-15426 A 20000624
WO 2001-
GB2810 W 20010625
AB The invention provides a protein framework which allows active
polypeptides e.g. ligands or antigens to be displayed at increased concn.
The inventors show that the lectin binding domains of collectins can be
replaced by a polypeptide of interest and that polypeptide can be
multimerised by the framework of the collectin and as a result displayed
in greater no. on a single structure. The inventors show that the
activity of polypeptides such as those of the TNF superfamily are
significantly enhanced when displayed in this way. The invention
demonstrated that multimeric fusion protein SP-D-CD154 was about 8 fold
more potent than trimeric CD154 in inducing B cell proliferation.
Multimeric fusion protein SP-D-CD154 also induced higher levels of
expression of ICAM-1 and CD86, compared to those of trimeric CD154.
SP-D-CD154 can potentially bind to 12 CD40 mol., compared to three mols.
with trimeric CD154, implying that the extent of receptor oligomerization
may influence the signals generated by CD40.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 7 OF 13 CAPLUS
COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:435124
CAPLUS <<LOGINID::20061019>>
DOCUMENT NUMBER: 135:45182
TITLE: Multimeric forms of TNF superfamily ligands
INVENTOR(S): Kornbluth, Richard S.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE
APPLICATION NO. DATE
---------- ---- -------- ----------
-- --------
WO 2001042298 A1 20010614
WO 2000-US7380 20000320
W: AU, CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI,
FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE
CA 2393659 AA 20010614 CA
2000-2393659 20000320
EP 1235853 A1 20020904 EP
2000-919485 20000320
R: AT, BE, CH, DE, DK, ES, FR, GB,
GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY
US 2005158831 A1 20050721
US 2005-87348 20050322

PRIORITY APPLN. INFO.: US 1999-454223 A 19991209
US 1998-111471P P 19981209
WO 2000-US7380 W 20000320
AB A method for constructing stable bioactive fusion proteins of the difficult to express tumor necrosis factor superfamily (TNFSF), and particularly members CD40L (CD154) and RANKL/TRANCE, with collectins, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these sol. fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be esp. useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addn., these and other TNFSF-***collecting*** ***fusion*** proteins present new possibilities for the expression of highly active, multimeric, sol. TNFSF members.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:310484 CAPLUS <<LOGINID::20061019>>
DOCUMENT NUMBER: 134:325200
TITLE: Vaccine compns. comprising antigens fused with antigen-presenting cell-binding domains of opsonins
INVENTOR(S): Segal, Andrew H.
PATENT ASSIGNEE(S): Genitrix, Ltd., USA
SOURCE: U.S., 21 pp., Cont.-in-part of U.S. Ser. No. 788,143, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6224870	B1	20010501	US 1998-7711	19980115
WO 9936507	A1	19990722	WO 1999-US894	19990115

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9922301	A1	19990802	AU 1999-22301	19990115
US 2001031264	A1	20011018	US 2001-789922	20010221
US 2002131974	A1	20020919	US 2001-790317	20010221
US 6632436	B2	20031014		

PRIORITY APPLN. INFO.: US 1997-788143 B2 19970124
US 1996-11047P P 19960125
US 1998-7711 A 19980115
WO 1999-US894 W 19990115
AB The invention provides compns. and methods for modulating immune responses

in subjects. The invention is based, at least in part, on the discovery
that an in-frame translation fusion of an antigen with an APC binding
domain of an opsonin forms a mol., i.e., a fusion polypeptide, which when
administered to a subject modulates an immune response to the antigen.
REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:753729 CAPLUS <<LOGINID::20061019>>
DOCUMENT NUMBER: 134:351860
TITLE: Development of chimeric collectins with enhanced
activity against influenza A virus
AUTHOR(S): Hartshorn, Kevan L.; White, Mitchell R.; Alan, R.;
Ezekowitz, B.; Sastry, Kedarnath; Crouch, Erika
CORPORATE SOURCE: Boston University School of Medicine, Boston, MA, USA
SOURCE: Advances in Experimental Medicine and Biology (2000),
479(Biology and Pathology of Innate Immunity
Mechanisms), 49-59
CODEN: AEMBAP; ISSN: 0065-2598
PUBLISHER: Kluwer Academic/Plenum Publishers
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 30 refs. Topics discussed include the functional
significance of variations in carbohydrate binding specificity and
quaternary structure of collectins with respect to influenza A virus
infection; and construction of collectin chimeras to det. the contribution
of specific domains to antiviral and opsonic activities.
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:459229 CAPLUS <<LOGINID::20061019>>
DOCUMENT NUMBER: 115:59229
TITLE: Methods and systems for generating and
collecting ***fusion*** fuel material
INVENTOR(S): Lautzenhiser, Theodore V.; Eisner, Melvin
PATENT ASSIGNEE(S): Amoco Corp., USA
SOURCE: Can. Pat. Appl., 17 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2005641	AA	19901212	CA 1989-2005641	19891215

PRIORITY APPLN. INFO.: US 1989-364936 A 19890612
AB Methods and systems are described for the generation and collection of T.
In particular, T is generated at a reducing electrode of a Galvanic cell
and thereafter biased so as to migrate to a selected surface of the
reducing electrode. T which is migrated to the selected surface and
coalesced thereon is then collected.

L1 ANSWER 11 OF 13 USPATFULL on STN
ACCESSION NUMBER: 2005:183444 USPATFULL <<LOGINID::20061019>>
TITLE: Multimeric fusion proteins of TNF superfamily ligands
INVENTOR(S): Kornbluth, Richard S., La Jolla, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005158831	A1	20050721

APPLICATION INFO.: US 2005-87348 A1 20050322 (11)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-454223, filed on 9 Dec 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-111471P	19981209 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Lisa A. Haile, J.D., Ph.D., DLA PIPER RUDNICK GRAY CARY US LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133, US
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1-15
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for constructing stable bioactive fusion proteins of the difficult to express turn or necrosis factor superfamily (TNFSF), and particularly members CD40L (CD 154) and RANKL/TRANCE, with collectins, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these soluble fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be especially useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addition, these and other TNFSF- ***collectin*** ***fusion*** proteins present new possibilities for the expression of highly active, multimeric, soluble TNFSF members.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 12 OF 13 USPATFULL on STN
ACCESSION NUMBER: 2004:292713
USPATFULL <<LOGINID::20061019>>
TITLE: Methods and compositions for treating ocular disease
INVENTOR(S): Fleiszig, Suzanne M.J., Oakland, CA, UNITED STATES
Evans, David J., Oakland, CA, UNITED STATES
Sack, Robert A., Brookhaven, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004229802	A1	20041118
APPLICATION INFO.:	US 2004-823819	A1	20040414 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-462913P	20030415 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1624
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The use of collectins and/or surfactant proteins for the treatment and prevention of ocular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 13 OF 13 USPATFULL on STN
ACCESSION NUMBER: 92:82537
USPATFULL <<LOGINID::20061019>>
TITLE: Storage ring fusion energy generator
INVENTOR(S): Russell, Joseph A., 600 Star Rte., Lompoc, CA, United States 93436

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5152955		19921006
APPLICATION INFO.:	US 1990-566054		19900809 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wasil, Daniel D.
LEGAL REPRESENTATIVE: Wedemeyer, Lowell R.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 6
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 967

AB This invention relates to adaptation of intersecting storage rings, of the same type used in high energy nuclear physics research, for power generation. The device is optimized for lower-energy beam paricles and higher beam current, adapted with a reaction chamber at the intersection of the rings to collect released fusion energy for conversion to electricity, and equipped with means to recapture scattered accelerated particles and reintegrate them into the focused beams for recirculation through the reaction chamber. The preferred beam particles, deuterium and tritium, are accelerated and injected into and focused by the storage rings, to collide nearly head on in the reaction chamber.

Non-colliding, accelerated beam particles are conserved by recovery, correction and recirculation, requiring relatively small amounts of input energy to maintain acceleration and focus of the beams, and thus remain energized for another collision attempt. Grid devices intercept scattered particles and recapture some of them for recirculation. Only those beam particles which scatter so widely as to evade recapture and those which actually react to produce thermonuclear fusion must be replaced and accelerated up to the energy sufficient to cause fusion.